ARTICLE | Company News
MediciNova, Meiji Seika Kaisha deal
November 6, 2006 8:00 AM UTC
Meiji granted MediciNova a worldwide license to develop and commercialize MN-447 and MN-462. The antithrombotic compounds are in preclinical development for cardiovascular disease. The license exclude...